FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer.

Radiology

From the Department of Radiation Oncology, Shandong University Cancer Center, Jinan, China (Y.W., S. Yuan, J.Y.); Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology (Y.W., J.L., S. Yuan, J.Y.) and Department of Nuclear Medicine PET Center, Shandong Cancer Hospital and Institute (L.M., J.R., S. Yan, H.W., Z.F.), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Rd, Jinan 250117, China; and Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China (Y.W., P.L., J.Y.).

Published: August 2023

Background The radiotracer fluorine 18 (F)-labeled fibroblast activation protein inhibitor (FAPI) has shown promise for visualizing several types of cancer, but the accuracy of F-FAPI compared with F-fluorodeoxyglucose (FDG) for the detection of lung cancer remains uncertain. Purpose To evaluate the effectiveness of F-FAPI-based PET/CT imaging for the diagnosis of primary and metastatic lung cancer lesions as compared with F-FDG PET/CT. Materials and Methods In this secondary analysis of a prospective trial, consecutively recruited patients from a single center with pathologically confirmed lung cancer were prospectively enrolled from December 2020 to April 2022 and underwent paired F-FAPI and F-FDG PET/CT examinations at intervals of more than 20 hours and within 7 days of each other. Histopathologic and clinical follow-up results were used as reference standards for final diagnoses. F-FAPI and F-FDG uptake were compared using the McNemar test or paired Student test. Diagnostic accuracy was compared between the two techniques by using the McNemar χ test. Results Sixty-eight participants (median age, 63 years [IQR, 58-68 years; range, 42-79 years]; 46 male [68%]) were evaluated. Compared with the mean tumor-to-background ratio (TBR) for FDG uptake, TBR for FAPI uptake was lower in primary lung tumors (25.3 ± 14.0 [SD] vs 32.1 ± 21.1; < .001) but higher in metastatic lymph nodes (7.5 ± 6.6 vs 5.9 ± 8.6; < .001) and bone metastases (8.6 ± 5.4 vs 4.3 ± 2.3; < .001). For diagnostic accuracy in a total of 548 lesions in 68 participants, compared with F-FDG PET/CT, F-FAPI PET/CT demonstrated a higher sensitivity (99% [392 of 397 lesions] vs 87% [346 of 397]; < .001), specificity (93% [141 of 151 lesions] vs 79% [120 of 151]; = .004), accuracy (97% [533 of 548 lesions] vs 85% [466 of 548]; < .001), and negative predictive value (97% [141 of 146 lesions] vs 70% [120 of 171 lesions]; < .001), but there was no evidence of a difference for positive predictive value (98% [392 of 402 lesions] vs 92% [346 of 377 lesions]; = .57). Conclusion F-FAPI PET/CT may be superior to F-FDG PET/CT for detecting lung cancer. © RSNA, 2023 See also the editorial by Zukotynski and Gerbaudo in this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.222785DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
f-fdg pet/ct
16
pet/ct
8
diagnosis primary
8
primary metastatic
8
metastatic lung
8
compared f-fdg
8
f-fapi f-fdg
8
mcnemar test
8
diagnostic accuracy
8

Similar Publications

This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.

View Article and Find Full Text PDF

We demonstrate that performing anatomical pulmonary resection by video-assisted thoracoscopic surgery without staplers or energy devices is feasible. This technique is an alternative for surgeons with limited access to expensive technologies.

View Article and Find Full Text PDF

Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.

BMC Pulm Med

January 2025

Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Objective: Lung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily.

View Article and Find Full Text PDF

The association between Chlamydia pneumoniae infection and prognosis in lung cancer patients: a prospective study.

BMC Infect Dis

January 2025

Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.

Background: The prognostic value of Chlamydia pneumoniae (Cpn) infection in postoperative lung cancer patients remains unclear. This study aimed to evaluate the association between Cpn infection and survival in lung cancer patients.

Methods: This study included 309 newly diagnosed primary lung cancer patients from three hospitals in Fuzhou, China.

View Article and Find Full Text PDF

The role of Box A of HMGB1 in producing γH2AX associated DNA breaks in lung cancer.

Sci Rep

January 2025

Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

An ideal chemotherapeutic agent damages DNA, specifically in cancer cells, without harming normal cells. Recently, we used Box A of HMGB1 plasmid as molecular scissors to produce DNA gaps in normal cells. The DNA gap relieves DNA tension and increases DNA strength, preventing DNA double-strand breaks (DSBs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!